Barr
Executive Summary
Authorized generic tamoxifen (Zeneca's Nolvadex) distributor files a motion to become a plaintiff-intervenor in Zeneca's federal lawsuit against Lilly alleging false and misleading promotion of Evista (raloxifene) for breast cancer. A hearing for the case is schedule for May 17 (1"The Pink Sheet" March 1, p. 27)
You may also be interested in...
Zeneca Support Of Nolvadex Risk Claim Includes Lawsuit Against Lilly Evista
Zeneca's expanded support for Nolvadex' breast cancer risk reduction claim includes a lawsuit to prevent Lilly from off-label promotion of its drug Evista for the same indication.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials